BioCryst Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
BioCryst Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.3%
Buyback Yield
Total Shareholder Yield | -0.3% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Dec 09BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.
Dividend Yield vs Market
BioCryst Pharmaceuticals Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (BCRX) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.3% |
Industry Average (Biotechs) | 2.4% |
Analyst forecast (BCRX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BCRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BCRX has not reported any payouts.